EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Laryngeal NUT Carcinoma With BRD4 :: NUTM1 Fusion: A 4‐Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy

Masafumi Kanno iD, Chiai Sasaki, Eiichi Kato iD, Hoshino Terada, Nobuhiro Hanai iD, Eiichi Sasaki iD, Mana Fukushima, Toshiki Masuishi iD, Keisuke Takanari, Yasuto Fukada, Yuto Miyazaki, Yuki Sonoda iD und 4 weitere

Cancer Reports · 2026

DOI: 10.1002/cnr2.70679 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Masafumi Kanno und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Otorhinolaryngology-Head and Neck Surgery, Department of Sensory and Locomotor Medicine, Faculty of Medical Sciences, University of Fukui…. Hauptthemen laut MEDLINE: Nuclear Proteins, Oncogene Proteins, Fusion, Laryngeal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nuclear protein in testis (NUT) carcinoma is a rare, aggressive malignancy driven by NUTM1 rearrangement, often misdiagnosed as squamous cell carcinoma, with no established standard therapy. This report describes the clinical course and treatment resistance in primary laryngeal NUT carcinoma and provides insights into potential mechanism‐based therapeutic approaches. Case A 30‐year‐old man with a laryngeal tumor was initially treated for poorly differentiated squamous cell carcinoma. Recurrent disease prompted re‐evaluation; NUT carcinoma was diagnosed by NUT immunohistochemistry, and the BRD4 :: NUTM1 fusion was confirmed by molecular analysis. A bromodomain and extra‐terminal (BET) inhibitor and alternating vincristine, doxorubicin, and cyclophosphamide (VDC)/ifosfamide and etoposide (IE) chemotherapy induced transient tumor regression, whereas vorinostat, immune checkpoint inhibitors, and other systemic therapies were ineffective. Disease progression was ultimately driven by uncontrolled locoregional recurrence. Autopsy revealed a massive infiltrative tumor with extensive locoregional invasion, whereas distant metastatic disease was limited to minute pulmonary nodules; death resulted from overwhelming infection secondary to uncontrolled locoregional progression rather than systemic metastasis.

Conclusion

Early molecular diagnosis and biologically informed multimodal strategies are essential for managing laryngeal NUT carcinoma and overcoming treatment resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuclear ProteinsOncogene Proteins, FusionLaryngeal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalTranscription FactorsCarcinomaOncogene ProteinsNeoplasm ProteinsHumansMaleAdultFatal OutcomeBromodomain Containing ProteinsCell Cycle ProteinsCombined Modality Therapy

Stichwörter der Autor:innen

BET inhibitorBRD4::NUTM1 fusionVDC/IE chemotherapyepigenetic therapylaryngeal NUT carcinoma

Substanzen

NUTM1 protein, humanNuclear ProteinsOncogene Proteins, FusionBromodomain Containing ProteinsBRD4-NUT fusion oncogene protein, humanTranscription FactorsBRD4 protein, humanCell Cycle ProteinsOncogene ProteinsNeoplasm Proteins

Autor:innen und Institutionen

  • Division of Otorhinolaryngology-Head and Neck Surgery, Department of Sensory and Locomotor Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
  • Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Pathology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Plastic and Reconstructive Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.

ORCID-Profile: Masafumi Kanno, Eiichi Kato, Nobuhiro Hanai, Eiichi Sasaki, Toshiki Masuishi, Yuki Sonoda, Tetsuji Takabayashi

Förderung

  • Japan Society for the Promotion of Science (JSPS) KAKENHI

Zitieren

APA

Kanno, M., Sasaki, C., Kato, E., Terada, H., Hanai, N., Sasaki, E., Fukushima, M., Masuishi, T., Takanari, K., Fukada, Y., Miyazaki, Y., Sonoda, Y., Kato, Y., Morikawa, T., Takabayashi, T., & Fujieda, S. (2026). Laryngeal NUT Carcinoma With BRD4 :: NUTM1 Fusion: A 4‐Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy. Cancer Reports. https://doi.org/10.1002/cnr2.70679

Vancouver

Kanno M, Sasaki C, Kato E, Terada H, Hanai N, Sasaki E, et al. Laryngeal NUT Carcinoma With BRD4 :: NUTM1 Fusion: A 4‐Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy. Cancer Reports. 2026. doi:10.1002/cnr2.70679

BibTeX
@article{Kanno2026,
  author = {Kanno, Masafumi and Sasaki, Chiai and Kato, Eiichi and Terada, Hoshino and Hanai, Nobuhiro and Sasaki, Eiichi and Fukushima, Mana and Masuishi, Toshiki and Takanari, Keisuke and Fukada, Yasuto and Miyazaki, Yuto and Sonoda, Yuki and Kato, Yukinori and Morikawa, Taiyo and Takabayashi, Tetsuji and Fujieda, Shigeharu},
  title = {Laryngeal NUT Carcinoma With BRD4 :: NUTM1 Fusion: A 4‐Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70679}
}
Kostenlos starten →